The mechanism of action is represented by the inhibition of the autophosphorylation of ALK gene and the molecular targets include IGF-1 R, InsR, and ROS1 and have an activity of 20 times higher against crizotinib–resistant tumor cell lines [87]. The gene discussed is ALK; the disease is neoplasm.